



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

*sch*

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/228,020 01/11/99 ISNER

J 46963-DIV

HM22/0302

DAVID G CONLIN  
DIKE BRONSTEIN ROBERTS & CUSHMAN  
130 WATER STREET  
BOSTON MA 02109

EXAMINER

VANDER VEGT, F

ART UNIT

PAPER NUMBER

1644

DATE MAILED:

*8*  
03/02/01

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner of Patents and Trademarks**

# Office Action Summary

Application No.

09/228,020

Applicant(s)

Isner et al

Examiner

F. Pierre VanderVegt

Group Art Unit

1644



☒ Responsive to communication(s) filed on Aug 21, 2000

☐ This action is FINAL.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire three month(s), ~~or thirty days, whichever is longer~~, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claim

☒ Claim(s) 1-64 ~~is/are~~ pending in the application.

Of the above, claim(s) 1-19, 21, and 22 ~~is/are~~ withdrawn from consideration.

☐ Claim(s) \_\_\_\_\_ is/are allowed.

☒ Claim(s) 20 and 23-64 ~~is/are~~ rejected.

☐ Claim(s) \_\_\_\_\_ is/are objected to.

☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.

## Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been  
☐ received.

☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_.

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

☒ Notice of References Cited, PTO-892

☒ Information Disclosure Statement(s), PTO-1449, Paper No(s). 3

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

### DETAILED ACTION

This application is a divisional of application serial number 08/744,882.

Applicant should amend the specification at page 1 to reflect the priority information as well as the status of the parent application.

5 New claims 23-64 were added by Applicant's amendment filed September 6, 2000.

Claims 1-64 are currently pending in this application.

### *Election/Restriction*

10 1. Applicant's election without traverse of Group III, claim 20, in Paper No. 4, filed August 21, 2000, is acknowledged.

**Claims 1-19 and 21-22 are withdrawn** from further consideration pursuant to 37 CFR 1.142(b) as being drawn to nonelected inventions, there being no allowable generic or linking claim. Election was made **without** traverse in Paper No. 4.

15 New claims 23-64 have been added as being dependent upon elected claim 20. The claims are drawn to the same invention as claim 20 and are being examined here as part of Group III.

Accordingly, **claims 20 and 23-64 are the subject of examination** in this Office Action.

### *Claim Rejections - 35 USC § 112*

20 2. Claims 20 and 23-64 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

25 Briefly, the claims are drawn to a "pharmaceutical product" for the treatment of an individual which is a composition comprising endothelial cell (EC) progenitors and a nucleic acid molecule encoding an endothelial cell mitogen. It is noted here that the nucleic acid molecule does not need to be incorporated into the EC progenitors. While the making of the pharmaceutical product is enabled, the use of the pharmaceutical product is not enabled for the following reasons. While progress has been made in recent years for *in vivo* gene transfer, vector

targeting *in vivo* to desired organs continues to be unpredictable and inefficient. This is supported by numerous teachings available in the art. For example, Miller et al. reviews the types of vectors available for *in vivo* gene therapy, and conclude that "for the long-term success as well as the widespread applicability of human gene therapy, there will have to be advances...targeting strategies outlined in this review, which are currently only at the experimental level, will have to be translated into components of safe and highly efficient delivery systems" (page 198, column 1). Deonarain is a 1998 publication which indicates that one of the biggest problems hampering successful gene therapy is the "ability to target a gene to a significant population of cells and express it at adequate levels for a long enough period of time" (page 53, first paragraph). Deonarain reviews new techniques under experimentation in the art which show promise, but is currently even less efficient than viral gene delivery (see page 65, first paragraph under Conclusion section). Verma et al. (published in 1997) reviews various vectors known in the art for use in gene therapy and the problems which are associated with each and clearly indicated that at the time of the claimed invention resolution to vector targeting had not been achieved in the art (see entire article). Verma discusses the role of the immune system in inhibiting the efficient targeting of viral vectors such that efficient expression is not achieved (see page 239 and 2nd and 3rd column of page 242. Verma also indicates that appropriate enhancer-promoter sequences can improve expression, but that the "search for such [useful] combinations is a case of trial and error for a given cell type" (page 240, sentence bridging columns 2 and 3). Crystal also reviews various vectors known in the art and indicates that "among the design hurdles for all vectors are the need to increase the efficiency of gene transfer, to increase target specificity and to enable the transferred gene to be regulated" (page 409). The specification fails to teach any specific targeting techniques, fails to provide any working examples which encompass vector targeting, and fails to direct the skilled artisan to any teachings of targeting strategies known in the art which would allow one of skill in the art to use the claimed pharmaceutical product without undue experimentation.

*Conclusion*

3. The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which Applicant may become aware in the specification.

5

4. Papers related to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. Papers should be faxed to Group 1640 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The fax phone number for official documents to be entered into the record for Art Unit 1644 is (703)305-3014.

10

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to F. Pierre VanderVegt, whose telephone number is (703)305-6997. The Examiner can normally be reached Tuesday through Friday and odd-numbered Mondays (on year 2001 365-day calender) from 6:30 am to 4:00 pm ET. A message may be left on the Examiner's voice mail service. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ms. Christina Chan can be reached at (703)308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist, whose telephone number is (703)308-0196.

15

20

F. Pierre VanderVegt, Ph.D.  
Patent Examiner  
Technology Center 1600  
February 26, 2001



F. PIERRE VANDERVEGT  
PATENT EXAMINER